ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) COMBINATION IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER COMPARE WITH FLUOROURACIL AND OXALIPLATIN COMBINATION (FOLFOX)
Abstract: Combinations of
Fluorouracil (FU) and biomodulator Leucovorin (LV) established as a standard
regimen for therapy of colorectal cancer with metastases. To give better
antitumor activity in colorectal cancer therapy, oxaliplatin is combined with
FU/LV and give significant improvement. Fluorouracil can only be given by
intravenous administration. This limitation raised effort to find alternative
drugs that can be given orally, such as capecitabine. Capecitabine is an oral
FU prodrug, with high oral bioavailability, highly accumulated in neoplastic
tissue to be converted in FU, and well tolerated. Some clinical studies
revealed effectivity of capecitabine plus oxaliplatin (XELOX) compared to FU/LV
plus oxaliplatin (FOLFOX).
Objective : This article is aimed to compare non inferiority of XELOX to
FOLFOX in colorectal cancer with metastases, viewed form primary outcomes and
secondary outcomes.
Results : XELOX was comparable to FOLFOX with some benefitsover FOLFOX.
Conclusion : XELOX could be considered as FOLFOX replacement as a
standard therapyfor colorectal cancer with metastases.
Keywords: XELOX, FOLFOX, non
inferior, primary outcome, secondary outcome
Author: Isnatin Miladiyah
Journal Code: jpkedokterangg160335
